Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

Business Wire February 10, 2022

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire February 3, 2022

UroGen Pharma to Present at Upcoming Conferences

Business Wire January 5, 2022

First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

Business Wire December 21, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 3, 2021

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Business Wire November 15, 2021

UroGen Pharma Announces Upcoming 2021 Conferences

Business Wire November 11, 2021

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

Business Wire November 10, 2021

UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021

Business Wire November 1, 2021

The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

Business Wire October 5, 2021

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

Business Wire September 23, 2021

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

Business Wire September 13, 2021

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 10, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 3, 2021

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Business Wire August 4, 2021

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

GlobeNewswire August 2, 2021

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

Business Wire July 28, 2021

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

Business Wire July 28, 2021

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

Business Wire July 14, 2021

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

Business Wire July 7, 2021